A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma

Autor: Eigentler, Thomas K., Kamin, Anne, Weide, Benjamin M., Breuninger, Helmut, Caroli, Ulrich M., Möhrle, Matthias, Radny, Peter, Garbe, Claus
Zdroj: In Journal of the American Academy of Dermatology 2007 57(4):616-621
Databáze: ScienceDirect
Externí odkaz: